Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Xeris Biopharma Holdings, Inc. XERS

Healthcare  —  Drug Manufacturers Specialty & Generic
9.10 0.15 1.68% as of 25 Sep
Market cap
$1.6B
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Xeris Biopharma Holdings, Inc. (XERS) Business Profile

Updated before January 2025

Company Overview

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a specialty pharmaceutical company headquartered in Chicago, Illinois. The company was founded in 2005 with the mission of developing and commercializing innovative therapies for patients with unmet medical needs. Xeris focuses on leveraging its proprietary formulation technology platforms to create ready-to-use injectable and infusible drug formulations. The company’s leadership team includes Paul R. Edick, who serves as the Chairman and Chief Executive Officer, and other experienced executives with deep expertise in the pharmaceutical and biotechnology industries. Xeris has grown significantly since its inception, driven by its commitment to improving patient outcomes and addressing critical gaps in healthcare.

Core Business Segments

Xeris operates in the specialty pharmaceutical sector, focusing on the development and commercialization of innovative therapies. Its core business segments include:

1. Endocrinology

Xeris offers products that address critical needs in endocrinology, particularly for patients with diabetes and other metabolic disorders. Key products include:

  • Gvoke® HypoPen®: A ready-to-use glucagon injection for the treatment of severe hypoglycemia in diabetic patients.
  • Gvoke® PFS: A pre-filled syringe version of glucagon for the same indication.

2. Neurology

The company is also active in the neurology space, developing treatments for neurological conditions. Key products include:

  • Keveyis®: The first and only FDA-approved treatment for primary periodic paralysis, a rare genetic disorder.

3. Drug Delivery Platforms

Xeris leverages its proprietary XeriSol™ and XeriJect™ formulation technologies to develop ready-to-use injectable and infusible drug formulations. These platforms enable the development of stable, liquid formulations of drugs that were previously only available in lyophilized (freeze-dried) forms, improving convenience and reducing preparation time for healthcare providers and patients.

Business Model

Xeris Biopharma’s business model is centered around innovation, patient-centric solutions, and strategic commercialization. The company generates revenue through:

  • Product Sales: Xeris markets its FDA-approved products, such as Gvoke® and Keveyis®, directly to healthcare providers and patients.
  • Partnerships and Licensing: The company collaborates with other pharmaceutical companies to develop and commercialize products using its proprietary formulation technologies.
  • Research and Development (R&D): Xeris invests heavily in R&D to expand its product pipeline and address unmet medical needs. The company’s focus on innovation ensures a steady stream of new products and formulations.

Strategic Direction

Xeris Biopharma is committed to driving growth through innovation, strategic partnerships, and market expansion. Key elements of its strategic direction include:

  • Pipeline Expansion: Xeris is actively developing new products and formulations to address unmet needs in endocrinology, neurology, and other therapeutic areas.
  • Global Market Expansion: The company aims to expand its presence in international markets, leveraging its existing product portfolio and partnerships.
  • Sustainability Goals: Xeris is focused on improving the sustainability of its operations, including reducing waste and optimizing its supply chain.
  • Digital Health Integration: The company is exploring opportunities to integrate digital health solutions into its product offerings, enhancing patient outcomes and engagement.

Competitive Landscape

Xeris operates in a competitive pharmaceutical market, facing competition from both large multinational companies and smaller specialty firms. Key competitors include:

  • Eli Lilly and Company: A major player in the diabetes market, offering products like glucagon and insulin therapies.
  • Novo Nordisk: Another leader in diabetes care, with a strong portfolio of insulin and glucagon products.
  • Amgen: Competes in the neurology space with treatments for rare diseases.
  • Other Specialty Pharma Companies: Smaller firms developing innovative therapies for rare and underserved conditions.

Xeris differentiates itself through its proprietary formulation technologies, patient-centric approach, and focus on addressing unmet medical needs.

Risk Factors

Like any pharmaceutical company, Xeris faces several risks that could impact its business:

  • Market Dependence: The company relies heavily on the success of its key products, such as Gvoke® and Keveyis®.
  • Regulatory Risks: The pharmaceutical industry is highly regulated, and changes in regulatory requirements could impact Xeris’s operations.
  • Supply Chain Disruptions: Global supply chain challenges could affect the availability of raw materials and manufacturing processes.
  • Competition: Intense competition from larger pharmaceutical companies and new market entrants poses a risk to Xeris’s market share.
  • R&D Uncertainty: The success of Xeris’s pipeline depends on the outcomes of clinical trials and regulatory approvals, which are inherently uncertain.

Recent Developments

Xeris has made significant progress in recent years, including:

  • Product Launches: The company launched new formulations of its existing products, improving patient convenience and expanding its market reach.
  • Partnerships: Xeris entered into strategic collaborations with other pharmaceutical companies to leverage its formulation technologies.
  • Regulatory Approvals: The company received FDA approval for new indications and formulations of its products.
  • Global Expansion: Xeris expanded its presence in international markets, including Europe and Asia.
  • COVID-19 Impact: The pandemic highlighted the importance of ready-to-use injectable formulations, increasing demand for Xeris’s products.

Investment Considerations

Investors considering Xeris Biopharma should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Xeris’s proprietary formulation platforms provide a competitive edge.
  • Strong Product Portfolio: The company’s FDA-approved products address critical unmet needs.
  • Growth Potential: Xeris has a robust pipeline and opportunities for global expansion.
  • Experienced Leadership: The management team has a proven track record in the pharmaceutical industry.

Risks

  • Market Dependence: Reliance on a few key products could impact revenue stability.
  • Regulatory Challenges: Changes in regulatory requirements could delay product approvals.
  • Competition: Intense competition from larger players poses a risk to market share.
  • Financial Performance: As a growing company, Xeris may face challenges in achieving profitability.

Conclusion

Xeris Biopharma Holdings, Inc. is a dynamic and innovative pharmaceutical company with a strong focus on addressing unmet medical needs. Its proprietary formulation technologies, robust product portfolio, and commitment to patient-centric solutions position it as a leader in the specialty pharmaceutical market. While the company faces risks such as market dependence and regulatory challenges, its growth potential and strategic direction make it an attractive investment opportunity. With a focus on innovation, global expansion, and sustainability, Xeris is well-positioned for future success in the evolving healthcare landscape.